11 min listen
PROMINENT – A Randomized Trial of Pemafibrate for Triglyceride Reduction in the Prevention of CVD
FromACCEL Lite: Featured ACCEL Interviews on Exciting CV Research
PROMINENT – A Randomized Trial of Pemafibrate for Triglyceride Reduction in the Prevention of CVD
FromACCEL Lite: Featured ACCEL Interviews on Exciting CV Research
ratings:
Length:
8 minutes
Released:
Feb 7, 2023
Format:
Podcast episode
Description
In this contemporary population of statin-treated patients with type 2 diabetes and hypertriglyceridemia, 1 in 10 developed a cardiovascular event by 3 years, and despite 20-30% reductions of triglycerides and what we call remnant cholesterol with a fibrate-like therapy, there was no clinical benefit. In this interview, Aruna Das Pradhan MD, MPH and Allen J. Taylor MD, FACC discuss PROMINENT – A Randomized Trial of Pemafibrate for Triglyceride Reduction in the Prevention of CVD. Subscribe on Apple Podcasts | Subscribe on Google Play | Subscribe to ACCEL
Released:
Feb 7, 2023
Format:
Podcast episode
Titles in the series (100)
ACCEL Lite: STRENGTH Trial: High-Dose Omega-3 Fatty Acids vs. Corn Oil: The benefits and risks of fish oil derivatives remain controversial. STRENGTH (Long-Term Outcomes Study to Assess Statin Residual Risk With Epanova in High Cardiovascular Risk Patients With Hypertriglyceridemia) showed no benefits from administration... by ACCEL Lite: Featured ACCEL Interviews on Exciting CV Research